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Purpose: To proof feasibility of hydrogel application in patients with advanced cervical cancer undergoing
chemo-radiation in order to reduce rectal toxicity from external beam radiation as well as brachytherapy.
Material and methods: Under transrectal sonographic guidance five patients with proven cervical cancer
underwent hydro gel (20 cc) instillation into the tip of rectovaginal septum adherent to posterior part of the visible
cervical tumor. Five days after this procedure all patients underwent T2 weighted transversal and sagittal MRI for
brachytherapy planning. MRI protocol included T2 weighted fast spin echo (FSE) imaging in sagittal, coronal and
para-axial orientation using an 1.5 Tesla MRI. Separation of anterior rectal wall and cervix was documented.
Results: Hydrogel application was uneventful in all patients and no toxicity was reported. Separation ranged from 7
to 26 mm in width (median 10 mm). The length of the separation varied between 18 and 38 mm (median 32 mm).
In all patients displacement was seen in the posterior vaginal fornix, and/or at the deepest part of uterine cervix
depending on the extension of the cul-de-sac in correlation to the posterior wall of the uterus. In patients with
bulky tumor and/or deep (vaginal) extend of peritoneal cavity tumour was seen mainly cranial from the
rectovaginal space and therefore above the hydrogeI application. Only in the extra-peritoneal (lower) part of the
cervix a good separation could be achieved between the rectum and cervix.
Conclusion: Hydrgel instillation in patients with cervial cancer undergoing chemoradiation is safe and feasible.
Because of the loose tissue of the cul-de-sac and its intra- and extraperitoneal part, hydrogel instillation of 20 cc did
not result in a sufficient separation of the cervix from anterior wall.Introduction
Primary chemoradiation (RCTX) is the treatment of
choice in patients with locally advanced and/or lymph
node positive cervical carcinoma [1]. Paradigm shift
from radiation to RCTX lead to an improvement with
regard to local control as well as progression free and
overall survival [2]. Analysis of patterns of recurrence
showed that locoregional control remains critical [3].
Nevertheless RCTX can be associated with considerable
acute and late gastrointestinal (GI) toxicity [1,4].
Reported grade 3 and 4 late GI toxicity is in the range of
4%–40% depending on target volumes and radiation* Correspondence: simone.marnitz@charite.de
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reproduction in any medium, provided the ortechniques used [5-8]. However, possible improvement
of local control due to dose escalation has to take GI
and genitourinary (GU) toxicity into account.
Compared with 3D era IMRT based techniques could
demonstrate lower rates of high grade toxicity [9-12].
Efforts have been made to better target definition for ex-
ternal beam radiation and dose escalation [13-15], dose
prescription and application of brachytherapy, as well as
simultaneous consideration of therapy related toxicity.
Some proposals for dose sparing to the small bowel like
treatment in prone position or use of bowel displace-
ment systems did not gain acceptance in clinical routine
[16,17].
Although external beam radiation (EBRT) as well as
brachytherapy (BT) may lead to rectal complications
only few data available concerning rectal toxicity in theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Grasters to the vaginal introitus in order to bring the
rectovaginal septum under tension before application.
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ity is limited because of different treatment regimens,
doses of EBRT and BT, dose prescriptions, application
techniques and toxicity scoring systems. In cervical can-
cer patients cumulative overall and ≥2 grade rectal tox-
icity has been recorded in 12%–19% [18,19].
Injection of human collagen into the space between
prostate and rectum in prostate cancer patients have
shown decline of rectal dose by 25%–50% [20-24].
Therefore this new technique was thought to be an
interesting option even for patients with cervical carcin-
oma undergoing EBRT and BT. A separation of at least
10–15 mm would be sufficient to achieve 80% rectal
dose reduction [20]. Present study was initiated to proof
feasibility of hydrogel application in patients with
advanced cervical cancer in order to reduce rectal tox-
icity. To our best knowledge the present study is the first
reporting of hydrogel application in patients with cer-
vical cancer.#
Figure 2 Instillation of the gel into the Douglas Space during
general anaesthesia, # application set with the two
components of the gel.Material and methods
This pilot study comprises five patients with proven cer-
vical cancer (age 31–69 years, BMI 20–49 kg/m2). FIGO
stages were IB1 pN1 in one, IIB in two and IIIB in two
patients, respectively. All patients underwent primary
RCTX as previously described [25]. During third week
of EBRT patients underwent implantation of Smit-
Sleeve® applicator under general anaesthesia (Varian,
Palo Alto, CA) for brachytherapy. During this procedure
hydro gel installation was also performed. Written
informed consent was given by all patients. The present
pilot study was IRB approved. Patient was placed in with
adducted legs placed on leg holders. The procedure
started by filling the bladder with 300 cc isotonic saline
solution. Under abdominal sonography external cervical
os was identified, dilated and Smit Sleeve was inserted.
After fixation of the applicator with non resorbable
sutures graspers were placed at 05.00 and 07.00 o’clock
at vaginal introitus. By pulling the graspers downwards
rectovaginal septum was brought under tension before
gel application (Figure 1). Now a vaginal sonography
probe was inserted into the rectum. Under transrectal
sonographic guide hydrogel applicator (SpaceOAR®,
Augmenix, Waltham, MA) was placed up to the tip of
rectovaginal septum adherent to posterior part of the
visible cervical tumour. Injection was done bringing the
two components of the gel (20 cc) together (Figure 2).
Five days after this procedure all patients underwent
T2 weighted transversal and sagittal MRI for brachyther-
apy planning. MRI protocol included T2 weighted fast
spin echo (FSE) imaging in sagittal, coronal and paraax-
ial orientation using an 1.5 Tesla GE Signa Excite (GE
Healthcare, Fairfield, CO, USA).Results
Hydrogel application was uneventful in all patients and
no late toxicity was reported. On axial and sagittal T2-
weighted MRI hydrogel was clearly visible as a hyperin-
tense region between anterior rectal wall and posterior
vaginal wall (Figures 1, 2, 3, 4 and 5). Extend of separ-
ation ranged from 7 to 26 mm in wideness (median
10 mm). The length of the separation varied between 18
and 38 mm (median 32 mm), (Table 1). In all patients
displacement was seen only in the posterior vaginal for-
nix and/or deepest part of uterine cervix depending on
the extension of the cul-de-sac in correlation to the pos-
terior wall of uterus. In patients with bulky tumor or








Figure 3 a and b: Patient BW. Transversal and sagittal pelvic MRI












Figure 4 a and b: Patient MB. Transversal and sagittal pelvic MRI
(T2-FSE) with the cervical carcinoma (1) vaginal gel (2), rectal
separation (3) and afterloading applicator in situ (4).
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therefore above the hydrogeI application (Figures 3, 4, 6, 7).
Only in the extra-peritoneal part of the cervix a good separ-
ation could be achieved between the rectum and cervix
(Figure 5).
After completion of primary RCTX patients under-
went gynaecologic examinations every 3 months. Add-
itionally post radiation diagnostic curettage was done in
order to exclude local recurrence at least 3 month after
completion of therapy. In 4/5 patients no vital tumor
cells were histologically found and they are free of dis-
ease 12 months after therapy. One patient had residual
tumour in the cervix and synchronous pulmonary
metastases.Discussion
Most data concerning rectal separation using hydrogel
were published on prostate cancer patients. First cadav-
eric study has shown a decrease of rectal volume receiv-
ing 70 Gy significantly from 23% baseline value to 15%,
4% and 0% with 5 mm, 10 mm and 15 mm separation,
respectively [20]. These data could be confirmed by
other authors in clinical use during EBRT demonstrating
a dose reduction to the anterior rectal wall by 50% [21].
This was associated with decreased risk for acute rectal
toxicity compared with historical control [22] and
improved quality of life [24]. Even for BT Prada et al.
[22] could demonstrate that measured rectal dose for
HDR boost was significantly lower by about 2 Gy in
prostate cancer patients.
To our best knowledge, the present study is the first







Figure 5 a and b: Patient BR. T2 weighted FSE in transversal and
sagittal orientation with cervical carcinoma (1) vaginal gel (2) and
rectal separation (3).
Figure 6 a and b: Patient LC. Transversal and sagittal pelvic MRI
(T2-FSE) with cervical carcinoma (1) and rectal separation (2).
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was to separate the rectum from the tumour infiltrated
cervix uteri and thus reducing radiation dose to the an-
terior rectal wall during both external beam and brachy-
therapy planning. Alternative hydrogel distension could
allow dose escalation without increasing risk for rectal
toxicity.
There are two anatomical characteristis in female pel-
vis. In contrast to male anatomy with narrow and tenseTable 1 Length and wideness of separation (cm)





5 3.77 1.04space between rectum and prostate (rectal fascia,
Denonville fascia) rectovaginal septum is larger and con-
tains more loose tissue. More volume of hydrogel would
be necessary to develop entire rectovaginal space. How-
ever, median separation in our pilot study was 10.5 mm,
which is in the range of the reported values from pros-
tate cancer patients [20]. The length of separation has
not been reported by other authors.
Second anatomical difference is the extent of the cul-
de-sac in correlation to uterine/vaginal posterior wall
which varies individually. In contrast to all studies on
prostate that showed useful rectal separation, for cervical
cancer we could only demonstrate a good separation for
the extraperitoneal part of the cervix and upper vagina
but no distension in the peritoneal part. This fact limits
the value of the method for brachytherapy applications
as well as EBRT. If by use of more hydrogel (approxi-









Figure 7 a and b. Patient MB. Transversal and sagittal pelvic MRI
(T2-FSE) with the cervical carcinoma (1) vaginal gel (2) and rectal
separation (3).
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separated, remains speculative. Just as by other authors
there was no toxicity from the instillation procedure in
our study [20-24].
Conclusion
Because of different anatomy in the female pelvis injec-
tion of 20 cc hydrogel does not seem to be a useful tool
for rectal separation and thus for rectal dose sparing in
patients with cervical cancer.
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